Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs IDH 305 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 18 Dec 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as Novartis paused all study start-up activities due to safety evaluation of IDH305 compound.
- 20 Sep 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2020.
- 20 Sep 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2020.